Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has announced that Iraj Ali, CEO, will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has announced that Iraj Ali, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 8:15 a.m. ET. This event will showcase their innovative work in precision T cell therapies aimed at treating solid tumors, specifically focusing on clonal neoantigens unique to each patient. A live and archived webcast of the presentation will be accessible via the Events & Presentations section on the Achilles website.
Details
News Market Reaction – ACHL
The recorded move for ACHL in the trading session of this news was +6.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.
A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with unresectable locally advanced and metastatic non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Further information:
Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.